Olivier Benveniste
Overview
Explore the profile of Olivier Benveniste including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
211
Citations
5179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naddaf E, Skolka M, Prokop L, Dimachkie M, Hogrel J, Benveniste O, et al.
Rheumatology (Oxford)
. 2025 Mar;
PMID: 40085004
Objectives: Inclusion body myositis (IBM) is characterized by slowly progressive muscle weakness making it challenging to detect weakness changes during a clinical trial. Trial participants receiving placebo may behave differently...
2.
Needham M, Badrising U, Beer K, Heim A, Doverty A, Panicker A, et al.
Clin Exp Rheumatol
. 2025 Feb;
43(2):309-315.
PMID: 40018747
Objectives: This paper aims to provide insight into the challenges and opportunities of conducting an investigator-led, international, multicentre clinical trial for Inclusion Body Myositis (IBM), a rare inflammatory myopathy. Methods:...
3.
Badrising U, Henderson R, Reddel S, Corbett A, Liang C, Reardon K, et al.
Clin Exp Rheumatol
. 2025 Feb;
43(2):316-325.
PMID: 40018746
Objectives: Inclusion body myositis (IBM) is a complex inflammatory muscle disease in adults over 40, with histological features of autoinflammation, cell stress and autophagic abnormalities, and marked clinically by relentless...
4.
Bolko L, Anquetil C, Llibre A, Maillard S, Amelin D, Dorgham K, et al.
Front Immunol
. 2025 Feb;
16:1529582.
PMID: 40013143
Objective: The objective of this study was to evaluate the presence of different types of interferon in idiopathic inflammatory myopathies (IIM) and their subgroups using ultrasensitive cytokine detection techniques (SIMOA)...
5.
Plomp L, Chassepot H, Psimaras D, Maisonobe T, Mensi E, Leonard-Louis S, et al.
Lancet Reg Health Eur
. 2025 Feb;
50:101192.
PMID: 39896961
Background: Immune checkpoint inhibitors (ICIs) may induce overlapping myositis/myasthenia gravis (MG) features, sparking current debate about pathophysiology and management of this emerging disease entity. We aimed to clarify whether ICI-induced...
6.
Lauletta A, Allenbach Y, Behin A, Evangelista T, Leonard-Louis S, Garibaldi M, et al.
J Neurol Sci
. 2025 Jan;
470:123400.
PMID: 39855012
Introduction: Certain types of muscular dystrophy (MD), notably facioscapulohumeral muscular dystrophy (FSHD), exhibit muscle fiber necrosis with regeneration and a nonspecific inflammatory process. Although rare, the coexistence of MDs and...
7.
Lauletta A, de Le Hoye L, Leonard-Louis S, Garibaldi M, Allenbach Y, Benveniste O
J Neurol
. 2025 Jan;
272(2):123.
PMID: 39812689
Objectives: Granulomatous myositis (GM) is a rare entity whose precise clinical features and therapeutic outcomes have not yet been well defined. Given the limited evidence, data from a large cohort...
8.
Staedler K, Allenbach Y, Salort-Campana E, Malfatti E, Rigolet A, Attarian S, et al.
Eur J Neurol
. 2025 Jan;
32(1):e70026.
PMID: 39804003
Background: Monoclonal gammopathy (MG) has been reported in association with numerous neurological disorders but the spectrum of MG-associated myopathies remains poorly described. Objective: To report a newly acquired myopathy associated...
9.
Zhu C, Han Y, Byun J, Xiao X, Rothwell S, Miller F, et al.
Arthritis Rheumatol
. 2024 Dec;
PMID: 39679859
Objective: Idiopathic inflammatory myopathies (IIMs, myositis) are rare systemic autoimmune disorders that lead to muscle inflammation, weakness, and extramuscular manifestations, with a strong genetic component influencing disease development and progression....
10.
Teboul A, Allenbach Y, Tubach F, Belin L, Cassius C, Demortier J, et al.
Rheumatology (Oxford)
. 2024 Nov;
PMID: 39589730
Objectives: To investigate factors associated with dermatomyositis (DM) complete clinical response and overall survival with a focus on the use of immunosuppressive therapies in patients with cancer-associated DM. Methods: We...